Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

218
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
218
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

719
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
719
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

443
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
443
Survival Tree01:19

Survival Tree

185
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
 Building a Survival Tree
Constructing a...
185
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

352
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
352
Censoring Survival Data01:09

Censoring Survival Data

285
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
285

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma.

Technology in cancer research & treatment·2026
Same author

Pretreatment Risk Model for Radiation-Induced Lymphopenia Is Associated With Adjuvant Durvalumab Efficacy in Patients With Unresectable Stage III NSCLC.

International journal of radiation oncology, biology, physics·2026
Same author

PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results.

Cancer metastasis reviews·2026
Same author

Master Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation.

JCO precision oncology·2025
Same author

A patient similarity-embedded Bayesian approach to prognostic biomarker inference with application to thoracic cancer immunity.

Journal of the Royal Statistical Society. Series C, Applied statistics·2025
Same author

Bayesian Counterfactual Machine Learning Individualizes Radiation Modality Selection to Mitigate Immunosuppression.

JCO clinical cancer informatics·2025
Same journal

A joint model for a longitudinal outcome and a progressive multistate model under a mixed observation scheme.

Statistical methods in medical research·2026
Same journal

Efficient semi-supervised estimation of optimal individualized treatment regimes with survival outcome.

Statistical methods in medical research·2026
Same journal

Asymptotic online FWER control for dependent test statistics.

Statistical methods in medical research·2026
Same journal

Regression analysis of misclassified current status data with potentially unknown test accuracy.

Statistical methods in medical research·2026
Same journal

Bayesian multivariate linear mixed-effects models with varied association structures.

Statistical methods in medical research·2026
Same journal

Inference about the ratio of age-standardized rates between two overlapping populations.

Statistical methods in medical research·2026
See all related articles

Related Experiment Video

Updated: Oct 22, 2025

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.5K

A survival mediation model with Bayesian model averaging.

Jie Zhou1, Xun Jiang2, Hong Amy Xia2

  • 1Quantitative Health Sciences, 2569Cleveland Clinic, USA.

Statistical Methods in Medical Research
|August 27, 2021
PubMed
Summary
This summary is machine-generated.

This study introduces a Bayesian framework to analyze cancer treatment effectiveness by linking tumor response to patient survival. The method improves understanding of treatment effects, aiding in the development of new cancer therapies.

Keywords:
Bayesian model averagingmediation analysisoncologysurrogate markers

More Related Videos

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

1.2K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K

Related Experiment Videos

Last Updated: Oct 22, 2025

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.5K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

1.2K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Trials

Background:

  • Assessing cancer therapy benefit is challenging, with phase III trials often failing to show significant survival improvements.
  • Current surrogate endpoints for tumor response are crucial for early trial phases but often insufficient for regulatory approval.
  • There's a need for robust methods to evaluate treatment effects, considering tumor response and survival outcomes.

Purpose of the Study:

  • To present a Bayesian mediation analysis framework to study relationships between cancer treatment, patient subgroups, tumor response, and survival.
  • To develop a methodology robust to model misspecification in analyzing complex treatment effects.
  • To provide statistical metrics for quantifying direct and indirect treatment effects via tumor response.

Main Methods:

  • Utilized a Bayesian framework combining mediation analysis and Bayesian model averaging.
  • Applied the methodology to a phase III randomized controlled trial in metastatic colorectal cancer.
  • Employed posterior inference and posterior predictive distributions for survival analysis.

Main Results:

  • Demonstrated the application of the Bayesian framework in a real-world clinical trial setting.
  • Quantified the direct and indirect effects of treatment on survival, with the indirect effect mediated by tumor response.
  • Provided statistical metrics to assess the contribution of tumor response to overall treatment efficacy.

Conclusions:

  • The proposed Bayesian framework offers a robust approach to dissecting treatment effects in oncology.
  • This methodology can enhance the evaluation of surrogate endpoints and inform the development of novel cancer therapies.
  • Improved understanding of treatment-response-survival relationships can aid in optimizing clinical trial design and drug approval processes.